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Context: Immunosuppressive agents are associatedwithprofoundmetabolic side effects including
new-onset diabetes and dyslipidemia after organ transplantation.
Objective: To investigated the effects of the cyclosporine A (CsA) or tacrolimus on glucose uptake
and insulin signalling inhumanadipocytesand their impacton the regulationof cellular trafficking
of the glucose transporter 4 (GLUT4).
Design:Human isolated adipocytes were incubatedwith therapeutic concentrations of either CsA
or tacrolimus, and glucose uptake and expression of insulin signaling proteins were assessed.
Furthermore, we studied effects of CsA and tacrolimus on the regulation of cellular trafficking of
the GLUT4 in differentiated human pre-adipocytes and L6 cells.
Results: CsA and tacrolimus had a concentration-dependent inhibitory effect on basal and insulin-
stimulated 14C-glucose uptake in adipocytes. Although phosphorylation at Tyr1146 of insulin re-
ceptor (IR) was inhibited by tacrolimus, the phosphorylation and/or protein levels of the insulin
signalling proteins IRS1/2, p85-PI3K, PKB, AS160 and mTORC1, as well as GLUT4 and GLUT1, were
unchanged by CsA or tacrolimus. Furthermore, CsA and tacrolimus reduced the GLUT4 amount
localized at the cell surface of differentiated human pre-adipocytes and L6 cells in the presence of
insulin. This occurred by an increased rate of GLUT4 endocytosis, with no change in the exocytosis
rate.
Conclusions: These results suggest that therapeutic concentrations of CsA and tacrolimus can
inhibit glucose uptake independent of insulin signalling by removing GLUT4 from the cell surface
viaan increased rateofendocytosis. Suchmechanisms can contribute to thedevelopmentof insulin
resistanceanddiabetes associatedwith immunosuppressive therapy. In addition, theymayprovide
novel pharmacological approaches for treatment of diabetes.
Immunosuppressive drugs are associated with hypergly-cemia, dyslipidemia and hypertension, which along
with obesity are the main features of the metabolic syn-
drome. In the nontransplant population, metabolic syn-
drome is associated with increased risk for cardiovascular
diseases and diabetes. The calcineurin inhibitors, cyclo-
sporine A (CsA) and tacrolimus, are the main immuno-
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suppressive agents used to prevent rejection after solid
organ transplantation, as well as for treatment of auto-
immune diseases (1). Despite the expected action on the
immune system, long-term treatment with either CsA or
tacrolimus is associated with metabolic toxic effects,
which have a negative impact in the patient’s long-term
outcome (2). Experimental and clinical studies suggest
thatCsAand tacrolimus are associatedwith increased risk
for developing new-onset diabetes after transplantation
(NODAT) (3). NODAT has been reported to occur in
15%–50% of the transplant recipients and is recognized
as a risk factor for cardiovascular diseases, graft rejection
and death (4, 5).
CsA and tacrolimus mediate their immunosuppressive
action by interrupting Ca2/calmodulin- calcineurin sig-
naling pathways in T cells, thereby blocking antigen-stim-
ulated gene expression of IL-2, a factor critical for T cell
proliferation. Studies in animals and humans indicate that
calcineurin inhibitors reduce pancreatic insulin synthesis
and secretion (6, 7). Furthermore, recent studies in both
mice and humans have indicated that treatment with cal-
cineurin inhibitors is associated with reduced insulin sen-
sitivity in peripheral tissues (8–10). However, the under-
lying mechanisms for glucose intolerance are not known,
and the effects ofCsAand tacrolimus inhumanadipocytes
have not been studied previously.
Glucose uptake into muscle and adipose tissue is the
major mechanism by which normal whole-body glycae-
mia levels are maintained (11). This process is stimulated
by insulin, andmediated by glucose transporters (GLUT),
mainly GLUT4. In the absence of insulin, only 5%–10%
of the total cellular GLUT4 content is present at the cell
surface in both adipocytes and muscle cells (12, 13). Skel-
etal muscle is the main tissue responsible for insulin-de-
pendent glucose uptake, whereas adipose tissue accounts
for only a small fraction (14). Despite this, mice with ad-
ipose-selective depletion of GLUT4 develop impaired glu-
cose tolerance, apparently due to insulin resistance in-
duced in muscle and liver (15). Thus, adipose tissue is
crucial in regulating glucosemetabolismbeyond its intrin-
sic contribution to whole-body glucose handling and sig-
naling, eg, via adipokines and neuroendocrine pathways,
it can contribute to insulin resistance and the development
of type 2 diabetes (16).
Themain objectives of this studywere to investigate the
direct effects of therapeutic concentrations of CsA and
tacrolimus on glucose uptake and on insulin signaling in
human isolated adipocytes. In addition, GLUT4 amount
and cellular distribution was addressed. Effects of CsA
and tacrolimus on endocytotic and exocytotic rates of the
GLUT4 transporterwere studied in L6myoblasts express-
ing myc-tagged GLUT4 (GLUT4myc).
Materials and Methods
Adipose tissue donors
Human abdominal subcutaneous (n 44) and omental (n
11) adipose tissue biopsies were obtained from 44 nondiabetic
subjects (19 men/25 women; age 23–70 years; body mass index
(BMI) 20–36 kg/m2). Subjects fasted overnight (10 hours) and
venous blood samples were collected for analysis of glucose,
insulin and lipids by routine methods at the Department of Clin-
ical Chemistry, Sahlgrenska University Hospital. Adipose tissue
biopsies were performed by needle aspiration from the lower
part of the abdomen after local dermal anesthesia with lidocaine
(Xylocain; AstraZeneca, Södertälje, Sweden), or by elective ab-
dominal surgery after induction of general anesthesia.
Clinical and biochemical characteristics of the adipose tissues
donors are shown in Table 1. Some of the subjects donating
adipose tissue in this studywere also part of a previous published
study elucidating metabolic effects of rapamycin (17). Subjects
with diabetes, other endocrine disorders, systemic illnesses or
malignancy, as well as ongoing medication with systemic glu-
cocorticoids and immune modulating therapies were excluded
from the study. The study protocol was approved by the Re-
gional Ethics Review Boards in Gothenburg and Uppsala. Writ-
ten informed consent was received from all subjects.
Isolation of human adipocytes and primary
preadipocytes
Isolated human adipocytes were obtained from biopsies after
collagenase type II digestion (from Clostridium histolyticum,
Sigma Chemical Co., St. Louise, MO, USA), in Hank’s medium
(InvitrogenCorporation, Paisley, UK) containing 6mMglucose,
4% BSA (Sigma), 0.15 M adenosine (Sigma), pH 7.4 for 60
minutes at 37°C in a shaking water-bath. Isolated adipocytes
were filtered through a 250 m nylon mesh and were washed
four times in Hank’s medium without glucose (4% BSA, 0.15
Madenosine and pH 7.4). The average cell diameter was mea-
sured in isolated adipocytes (18).
Human primary preadipocytes (n 4) were isolated and cul-
tured inDMEM:F12 supplementedwith10%FBSand1%PEST
in Lab Tek II chamber glass slides (Nalgene Nunc International,
Naperville, IL, USA). Confluent preadipocytes were differenti-
ated andwere incubatedwith orwithoutCsAor tacrolimus (100
nM) for 75 minutes, and 6 nM insulin was added in the last 20
minutes. Cells were used to GLUT4 immunofluorescence anal-
ysis. See Supplemental Material andMethods for further details
on primary preadipocytes isolation and differentiation
procedure.
Culture of adipocytes and glucose uptake
assessment
To investigate the effects of short-term preincubations (15
minutes) with either CsA (Sigma, 1–1000 nM) or tacrolimus
(Sigma, 1–1000 nM) on glucose uptake, isolated subcutaneous
NODATNewonset diabetes after transplantation; p70S6K1 p70 ribosomal S6 kinase; PEST
Penicillin-streptomycin; PI3K Phosphatidylinositol 3-kinase; PKB Protein kinase B
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and omental adipocytes (n 8–17 and n 8, respectively) were
diluted to a lipocrit of 5% inHank’smedium (4%BSA, 0.15M
adenosine andpH7.4)without glucose.Measurement of cellular
D-[U-14C]-glucose uptake was performed according to a previ-
ously validated technique for human adipocytes, that reflects
rate of transmembrane glucose transport (19). See Supplemental
Material and Methods for further details.
To further investigate the effects of long-term preincubations
(20h) of either CsA or tacrolimus on glucose uptake, the subcu-
taneous and omental adipocytes (n 8 and n 5, respectively)
were incubated in DMEM (6 mM glucose, 10% FBS, 1% PEST,
Invitrogen) in the absence or presence of either CsA or Tacroli-
mus (100 nM), at 37°Cunder a gas phase of 5%CO2with gentle
agitation (30 rpm) in a culture chamber (20). After incubation
the cells were washed and diluted in Hank’s medium without
glucose to measure glucose uptake, as above. The viability of
adipocytes was not significantly affected after 24 hours incuba-
tion with CsA or tacrolimus (90 to 100%, pns), when com-
pared to untreated cells.
Immunoblotting of adipocyte lysates
For immunoblotting analysis, isolated subcutaneous adi-
pocytes were diluted in Hank’s medium (4% BSA, 0.15 M
adenosine and pH 7.4) with 5.6 mM glucose, and were prein-
cubated with either CsA or tacrolimus (100 nM) for 15 minutes
(n  5) or 20 hours (n  4–6). Cell lysates were prepared and
immunoblotting was performed as described in Supplemental
Materials and Methods.
Culture of L6 cells and assessment of 2-deoxy-D-
[3H] glucose uptake and plasma membrane GLUT4
L6 cells that stably expresses the GLUT4 protein containing
a fourteen amino acid epitope human c-myc, were kindly pro-
vided by Dr. A. Klip (The Hospital for Sick Children, Toronto,
Ontario, Canada), and were cultured as previously described
(21). The L6 cells were maintained in MEM- (Invitrogen) sup-
plemented with 10% FCS (at 37°C, 5% CO2). For immunoflu-
orescence analysis cells were grown in Lab Tek II chamber glass
slides. For glucose uptake and plasma membrane preparation,
L6 cells were differentiated in medium supplemented with 2%
FCS into myotubes within 7 days after seeding. The cells were
serum-starved for3–4hours andwere incubatedwithorwithout
CsAor tacrolimus (100nM) for 75minutes,with orwithout 100
nM insulin (Humulin R, Lilly, Solna, Sweden) during the last 20
minutes. 2-Deoxy-D-[3H] glucose (2-DG) uptake was measured
according to a previously validated technique for L6 cells (22).
Plasma membrane preparations were performed using a com-
mercial protein extraction kit (abcam, Cambridge, UK), to an-
alyze GLUT4 translocation to the plasma membrane. Equal
amount of protein (6–8 g) were subjected to immunoblotting
against anti-GLUT4. Anti-Na/KATPase (Cell Signaling) was
used as a plasma membrane fraction marker. See Supplemental
Material and Methods for further details.
GLUT4myc internalization (endocytosis) and
externalization (exocytosis) in L6 cells
L6 cells expressing GLUT4myc allow reproducible measure-
ments of the cell surface myc-epitope, and they are well-charac-
terized for assessment of GLUT4 traffic (21, 23). GLUT4myc
internalization and externalization was measured in L6 myo-
blasts by an antibody-coupled colorimetric absorbance assay as
previously described (23), with some modifications. See Supple-
mental Material and Methods for further details.
Immunofluorescence microscopy of differentiated
human preadipocytes and L6-GLUT4 myc cells
Following incubation, the cells were washed with ice-cold
PBS and then fixed in 4% paraformaldehyde/PBS (Histolab
Products AB, Gothenburg, Sweden) for 20 minutes. After fixa-
Table 1. Characteristics of the adipose tissue donors
(n  44).
Variable Value
Sex
(male/female;
n)
19/25
Age (years) 50  13
Body mass
index (kg/
m2)
27.7  4.0
Waist-hip ratio
(WHR)
0.92  0.09
Systolic blood
pressure
(mmHg)
132  18
Diastolic blood
pressure
(mmHg)
83  11
Subcutaneous
adipocyte
diameter
(m)
a
99.8  11.7
Omental
adipocyte
diameter
(m) b
88.4  19.7
HbA1c (mmol/
mol, IFCC) c
34  4
Glucose
(mmol/liter)
5.1  0.6
Insulin (mU/
liter)
8.6  6.0
HOMA-IR d 1.7  1.1
Body fat mass
(%)
32.1  7.1
Triglycerides
(mmol/liter)
1.2  0.4
Cholesterol
(mmol/liter)
6.0  1.3
LDL-
cholesterol
(mmol/liter)
3.9  1.1
HDL-
cholesterol
(mmol/liter)
1.7  0.6
Data are means  SD
a n  44; b n  11; c Normal range 27–46 mmol/mol (IFCC standard);
d
Homeostasis model assessment-estimated insulin resistance,
calculated as: fasting insulin (mU/liter)  fasting glucose (mM)/22.5;
HbA1c, glycosylated haemoglobin; LDL, low-density lipoprotein; HDL,
high density lipoprotein
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tion, part of the L6-GLUT4myc cells were permeabilized with
0.1% Triton X100 (Sigma) in PBS for total cell immunofluores-
cence and part were left nonpermeabilized for cell surface im-
munofluorescence. Cells were blocked with 20% FCS in PBS
during 30 minutes. Differentiated human preadipocytes were
probedwith anti-GLUT4antibody (1:200, antibody recognizing
several epitopes in various regions of GLUT4 potentially includ-
ing extracellular parts, fromMillipore Corporation, Darmstadt,
Germany), while L6-GLUT4 myc cells were probed with anti-
c-myc (diluted 1:100, Sigma). The secondary antibody (Alexa
Fluor594goat antirabbit IgG,1:500,MolecularProbes, Eugene,
OR, USA), was added for 1 hour. The cells were washed, labeled
with DAPI for nuclear staining and mounted in vectashield
H-1000 (Vector Laboratories, Burlingame, CA, USA) for immu-
nofluorescence microscopy. Images were processed with NIH
ImageJ software (Java-based public version). See Supplemental
Material and Methods for further details.
Statistical Analysis
Differences between control and treated conditions in human
adipocytes were performed pair-wise using Wilcoxon signed-
rank test or paired Student’s t test, as ap-
propriate. Thus, comparisons between
treated and untreated adipocytes were
performed pair-wise within the same
subject and experiment tominimize con-
founding variables. Unpaired Student´s t
test was used for differences between
control and treated conditions in L6
cells. Results are given as mean  SEM,
or as indicated. A P-value  0.05 was
considered statistically significant. Sta-
tistical analyses were performed using
the SPSS package version 18 (SPSS Inc.,
Chicago, IL).
Results
Cyclosporine A (CsA) and
tacrolimus inhibit glucose
uptake in human adipocytes
Short-term incubation of subcu-
taneous isolated adipocytes with
CsA (5–1000 nM) or tacrolimus (1–
1000 nM) significantly decreased
basal and insulin-stimulated (6 nM)
glucose uptake in a dose depended
manner by up to 40% (Figure 1A).
The inhibitory effect on insulin-stim-
ulated glucose uptake was similar
when a lower concentration of insu-
lin (0.15 nM) was used (data not
shown). In omental adipocytes, sim-
ilar effectswere observed after short-
term incubation, and both basal and
insulin-stimulated (6 nM) glucose
uptake were significantly decreased
byup to30%(Figure 1B) upon treatmentwith either drug.
After long-term incubation with CsA or tacrolimus, basal
glucose uptakewas inhibited by10and20%, respectively,
while insulin-stimulated glucose uptake was inhibited by
11 and 25%, in subcutaneous adipocytes (Figure 1C). In
omental adipocytes, neither CsA or tacrolimus signifi-
cantly affected basal glucose uptake, while insulin-stimu-
lated glucose uptake was inhibited by15%. Moreover,
short-term preincubation with CsA or tacrolimus (100
nM) inhibited glucose uptake stimulated by okadaic acid
by 20% (Figure 1D).
Effects of CsA and tacrolimus on insulin signaling
CsA and tacrolimus did not change total insulin recep-
tor (IR) protein levels after 15 minutes or 20 hours pre-
incubations (Figure 2A and B). Instead, tacrolimus re-
duced insulin-stimulated IR Tyr1146 phosphorylation at
both incubation times by30% (P0.05, Figure 2A and
Figure 1. Cyclosporine A (CsA) and tacrolimus reduce glucose uptake in subcutaneous and
omental adipocytes. A: Freshly isolated human subcutaneous adipocytes (n  5–9) were
preincubated during 15 minutes with or without different concentrations of CsA or tacrolimus (1
–1000 nM) and the incubation continued with or without insulin stimulation (6 nM) for an
additional 15 minutes, before D-[U-14C]-glucose was added, and glucose uptake was then
assessed during the following 45 minutes. *P  .05 and #P  .05 CsA and tacrolimus treated vs.
untreated. B and C: Freshly isolated human subcutaneous and omental adipocytes were
preincubated short-term (15 minutes) (B) and long-term (20 hours) (C) with CsA or tacrolimus
(100 nM) and thereafter glucose uptake was measured as previously explained. (B, n  17 and
n  8; C, n  8 and n  5 for subcutaneous and omental adipocytes, respectively). Total
incubation times were 75 minutes (short-term) and 21 hours (long-term). *P  .05 and ***P 
.001 CsA and tacrolimus treated vs. untreated. D: Freshly isolated human subcutaneous
adipocytes were preincubated during 15 minutes with CsA or tacrolimus (100 nM) and the
incubation continued with okadaic acid (1 M) as well as with or without insulin (6 nM) for an
additional 15 minutes, and thereafter as previously reported (n  5). *P  .05 CsA and
tacrolimus treated vs. untreated. OkAc, okadaic acid.
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B). In addition, CsA or tacrolimus did not change the pro-
tein levels or the insulin-stimulated phosphorylation of
insulin receptor substrate (IRS) 1, protein kinase B (PKB),
PKB substrate of 160 kDa (AS160), mammalian target of
rapamycin (mTOR) or its downstream target p70S6K
(Figure 2C and Supplemental Figure 1). Similar results
were obtained for IRS2, p85-PI3K, GLUT4 and GLUT1
protein levels.
CsA and tacrolimus reduce the amount of GLUT4
at the cell surface in human adipocytes
Fluorescence labeling with anti-GLUT4 in the plasma
membrane of adipocytes is shown in Figure 3. Insulin in-
creased by4-fold the amount of GLUT4 at cell surface,
compared with basal (Figure 3). Incubation with CsA or
tacrolimus (100 nM) significantly reduced the amount of
insulin-stimulated GLUT4 at the adipocyte surface by
60% (Figure 3), and had no effect
on basal amount of GLUT4 at cell
surface (data not shown).
CsA and tacrolimus reduce
insulin-stimulated glucose
uptake and plasma membrane
GLUT4 levels in L6 cells
Short-term incubation of L6 cells
with CsA or tacrolimus (100 nM),
significantly reduced insulin-stimu-
lated (100 nM) glucose uptake by
20% (Figure 4A), but had no effect
on basal glucose uptake. Based on
the inhibitory effects of CsA and ta-
crolimus on insulin-stimulated glu-
cose uptake in L6 cells, we further
investigate whether the treatment
could modulate the levels of GLUT4
at the plasma membrane, measured
following fractionation of L6 cells.
CsA and tacrolimus significantly re-
duced the plasma membrane levels
of GLUT4 by40% (Figure 4B). In
addition, nonpermeabilized and per-
meabilized L6-GLUT4myc cells
were exposed to antimyc antibody
for immunofluorescence analysis of
cell-surface and total GLUT4myc,
respectively (Figure 4C and D). In
nonpermeabilized L6 cells, a low
level of surface GLUT4was detected
in the basal state, and the intensity of
the staining increased by 2-fold (P
.01) upon insulin stimulation (Figure
4C). Pretreatment of the cells with
either CsA or tacrolimus reduced the amount of insulin-
stimulated GLUT4myc at the cell surface (Figure 4C), by
20%–30% (P  .05). In contrast, insulin did not signifi-
cantly alter the total GLUT4myc, and neither CsA or ta-
crolimus had any effect (NS, Figure 4D).
CsA and tacrolimus increase the GLUT4
endocytosis in L6 cells
To further investigate the effects of CsA and tacrolimus
on the GLUT4 cycling with the plasma membrane, we
studied the effects of CsA and tacrolimus in the GLUT4
exocytosis and endocytosis. GLUT4myc internalizes with
similar rate constants for endocytosis in basal and insulin-
stimulated conditions (ken 0.29 and 0.30 minutes
-1, re-
spectively, Figure 5A and B). CsA or tacrolimus increased
the insulin-stimulated rate ofGLUT4myc endocytosis (ken
Figure 2. Effects of Cyclosporine A (CsA) and tacrolimus on insulin signaling proteins. Freshly
isolated human subcutaneous adipocytes were incubated without (control) or with CsA and
tacrolimus (100 nM) for 15 minutes (A) or 20 hours (B-C), prior to insulin stimulation (6 nM) for
additional 15 minutes. Immunoblotting analysis showed that tacrolimus reduces insulin-
stimulated IR Tyr1146 phosphorylation after short- (A) or long-term (B) incubation (n  4–6).
Data are mean  SEM of densitometry analysis of insulin-stimulated IR Tyr1146 phosphorylation
after CsA and tacrolimus treatment compared to untreated adipocytes (set to 1) and normalized
to the respective protein levels (p-IR/IR). *P  .05 and **P  .01 CsA and tacrolimus treated vs.
untreated. (C) CsA or tacrolimus had no effect on total IRS1/2 and phosphospecific antibody
against p-IRS1 Tyr612, total p85 subunit of PI3K, total PKB and phosphospecific antibodies
against p-PKB Ser473 and Thr308, total AS160 and phosphospecific antibody against p-AS160
Thr642, total GLUT4, total GLUT1, total mTOR and p70S6K and phosphospecific antibodies
against p-mTOR Ser2448 and p-p70S6K Thr421/Ser424. n  4–6. Results show representative
blots. Densitometry analyses are shown in Supplemental Figure 1.
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insulin  0.30 minutes-1, ken insulinCsA  0.39 minutes
-1 and ken
insulintacrolimus0.44minutes-1, Figure5B), but hadmodest effect on the
basal endocytosis (ken basal0.29minutes
-1,kenCsA0.31minutes
-1 and
ken tacrolimus 0.33 minutes
-1, Figure 5A). In addition, CsA and tacroli-
mus, significantly decreased the fraction of cell surface GLUT4myc re-
maining at the cell surface by up to 30%, after 10 or 20 minutes incu-
bations and in insulin-stimulated conditions (Yinsulin 0.30,YCsAinsulin
 0.19 and Ytacrolimusinsulin  0.21, Figure 5B). Insulin treatment in-
creased by  2-fold the GLUT4myc exocytosis, but neither CsA or ta-
crolimus effect the basal or insulin-stimulated GLUT4myc exocytosis
(Figure 5C).
Discussion
In this study we demonstrate that CsA and tacrolimus, at
therapeutic concentrations commonly used in clinic, in-
hibited glucose uptake in human subcutaneous and omen-
tal adipocytes and in L6 muscle cells. This appears to be
independent of the insulin signaling cascade, and removal
of GLUT4 from the cell surface via increased rate for en-
docytosis may be a novel mechanism for the diabetogenic
effects of the calcineurin inhibitors. These mechanism
clearly differ from that of another class of immunosup-
pressive agents, namelymTOR inhibitors, andwe recently
reported major alterations in insulin signaling and action
in human adipocytes exposed to rapamycin (17).
Most the studies that have examined the diabetogenic
effects of CsA and tacrolimus, indi-
cate that these calcineurin inhibitors
inhibit pancreatic insulin synthesis
and secretion (6), but a reduction in
peripheral insulin sensitivity has also
been suggested (9, 10). The reduc-
tion of glucose uptake in human adi-
pocytes after incubation with either
CsA or tacrolimus, as well as in L6
cells, suggests that these drugs may
contribute to the development of
NODAT by inhibiting glucose up-
take in insulin-sensitive cells. Fur-
thermore, using immunofluores-
cencewewere able to show that CsA
and tacrolimus significantly contrib-
ute to reduced insulin-stimulated
presence of GLUT4 in the plasma
membrane of differentiated human
preadipocytes and L6 cells. Due to
the challenge to obtain enough adi-
pocytes to isolate the plasma mem-
brane, we decided to further explore
the effects of both drugs in the pres-
ence of GLUT4 in the plasma mem-
brane in a cell line, the L6 cells. Plasmamembrane isolated
from L6 cells further confirmed that both drugs signifi-
cantly contribute to reduced insulin-stimulated presence
of GLUT4 in the plasma membrane. This data gives new
insight to the mechanism by which calcineurin inhibitors
impair glucose handling in peripheral tissues.
Results from several randomized clinical trials and
meta-analyses, have suggested that tacrolimus is more di-
abetogenic than CsA (24, 25), although this has not been
confirmed by others (26). In our study, however, the dose
response relationships with respect to impairment of glu-
cose uptake were similar for the two drugs. These effects
of CsA and tacrolimus could be detected at low concen-
trations (1–5 nM) thatwere even below the recommended
therapeutic ranges for both CsA (40–80 nM) and tacroli-
mus (6–12 nM) (27) and with similar dose-response
effects.
In addition, we show that CsA and tacrolimus inhibit
glucose uptake stimulated by okadaic acid. Okadaic acid,
a protein phosphatases type 1 (PP1) and 2A (PP2A) in-
hibitor, stimulates adipocyte PKB kinase activity and glu-
cose transport independent of PI3K activation (28). These
observations support that CsA and tacrolimus mediate
their effects independent or downstream of PI3K
activation.
A reduction in IR Tyr1146 activation by 30% was
found in adipocytes incubated with tacrolimus, when
Figure 3. Cyclosporine A (CsA) and tacrolimus inhibit the amount of GLUT4 localized at the
adipocyte surface. Human preadipocytes differentiated into adipocytes were serum starved and
incubated without or with CsA or tacrolimus (100 nM) during 75 minutes, and insulin (6 nM)
was added in the last 20 minutes. Cells were fixed and probed with anti-GLUT4 and with Alexa
Fluor 594 goat antirabbit IgG. A: Immunofluorescence was detected using laser confocal
microscopy. A representative image of 4 separate experiments is presented. Bars represent 25
m. B: The fluorescence intensity (mean pixel density per are unit) was quantified and is
represented as % relative to insulin. *P  .05 and **P  .01.
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compared with untreated adipocytes. However, the con-
centration of insulin required to maximally activate glu-
cose transport elicits only about 15% of the maximal re-
ceptor kinase activity (29), compatible with the spare
receptor concept (30). Indeed, the observed inhibitory ef-
fect on the phosphorylation of the
IR, was not associated with any
change in expression or phosphory-
lation of the proximal insulin signal-
ing cascade proteins (IRS1/2, p85-
PI3K, PKB, mTOR, p70S6K), or
GLUT4 and GLUT1 protein levels.
Taken together, these data indicate
that the inhibitory effects of CsA and
tacrolimus on glucose uptake are not
mediated through effects on the early
steps of the insulin signaling cascade.
Therefore we propose that the re-
duced insulin-stimulated glucose up-
take observed in human adipocytes
treated with either CsA or tacroli-
mus could be due to effects on the
intracellular trafficking of GLUT4,
independent of the insulin signaling
machinery. We also demonstrated
that in L6 cells, CsA and tacrolimus
increased the insulin-stimulated rate
of GLUT4 endocytosis, but they had
no effect on the exocytosis traffick-
ing. We believe that this mechanism
may be similar in human adipocytes,
as CsA and tacrolimus also reduced
the amount ofGLUT4 at the cell sur-
face in these cells. However, differ-
ent effects of CsA and tacrolimus on
basal glucose uptake in human adi-
pocytes and L6 cells could be due to
the different cell models, or differ-
ences in the GLUT4 internalization
in these cells (31). Chronic insulin
treatment has been reported to re-
duce glucose transport and to double
the rate constants for glucose endo-
cytosis in rat adipocytes (32). These
effects are ameliorated by inclusion
of metformin in the culture medium,
and this might be mediated by an
AMPK-dependent reduction in en-
docytosis (32, 33). In addition, met-
formin was shown to improve im-
munosuppressive agents-induced
hyperglycemia in a rodent model
(34). Whether metformin can pre-
vent the CsA and tacrolimus effects on glucose uptake in
human adipocytes should be addressed in future studies. It
could thus be hypothesized that targeting this endocytic
pathway with metformin or with novel pharmacological
Figure 4. Cyclosporine A (CsA) and tacrolimus reduce glucose uptake and the amount of
GLUT4 at the plasma membrane in L6 cells. L6 cells that stably express GLUT4myc were
preincubated in the presence or absence of CsA or tacrolimus (100 nM) for 75 minutes, and 100
nM insulin was added in the last 20 minutes. Cell were used to (A) measure 2-deoxy-D-[3H]
glucose uptake (n  8) and (B) changes in plasma membrane GLUT4 protein levels (n  6). A
representative western-blot is shown. The blots were quantified and the histogram shows the
densitometry analysis of the Western-blots. Na/K ATPase was used as a plasma membrane
fraction marker. Data are presented as mean  SEM and they are expressed as % relative to
insulin. *P  .05, ** P  .01. (C-D) L6 cells were processed for immunofluorescence analysis
with antimyc antibody (red) at the cell-surface in nonpermeabilized L6-GLUT4myc cells (n  5, C)
and for total myc in permeabilized L6-GLUT4myc cells (n  3, D). Cell nuclear DNA was stained
with DAPI (blue). Immunofluorescence was detected using fluorescence microscopy. The cell-
surface myc fluorescence intensity was quantified and normalized to the respective cell number
and calculated as % relative to insulin-stimulated cells (set to 1). Basal: 0.54 (P  .01),
InsulinCsA: 0.81 (P  .05), Insulintacrolimus: 0.75 (P  .01) compared to insulin alone.
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approaches may be away to increase cell-surface GLUT4.
Since transmembraneglucose transport is considered tobe
rate-limiting for glucose disposal in diabetes, such a treat-
ment could mitigate impaired glucose metabolism caused
by calcineurin inhibitors and, moreover, it could poten-
tially improve glycaemic control in other types of diabetes,
including type 2.
The question remains, about how CsA and tacrolimus
increase the rate of GLUT4 endocytosis. The effect of CsA
and tacrolimus on other proteins involved in docking, fu-
sion and endocytosis of GLUT4 vesicles (eg, adaptor pro-
tein 2, transferrin receptor) should be further studied,
since changes in the protein composition of GLUT4 ves-
icles may alter their subcellular distribution (35). Another
intracellular mechanism required for insulin-mediated
GLUT4 trafficking is dynamic remodelling of actin fila-
ments (36). Interestingly, calcineurin regulates actin dy-
namics in renal podocytes (37), andmice lacking calcineu-
rin A have reduced insulin-stimulated glucose uptake
and develop insulin resistance (38). Calcineurin is a serine
phosphatase, known to be involved in the regulation of
phosphodiesterases and consequently in cAMP degrada-
tion (38). Therefore, it has a potential role in hormonal
signaling and regulation of metabolism. It is also attempt-
ing to speculate that calcineurin inhibition could affect
cytoskeleton function and thus alter vesicle trafficking.
The significance of calcineurin GLUT4 traffickingmay be
addressed by silencing calcineurin expression in human
cells in future experiments.
Limitations of our study include its descriptive nature.
Moreover, the same subjects were not used for all analysis
and different cell types (primary human adipocytes, dif-
ferentiated humans preadipocytes and L6 cells) were used
for experiments on cellular GLUT4 localization and traf-
ficking. In addition, the in vitro models do not include the
complex cross-talk between tissues occurring in the reg-
ulation of glucose metabolism in vivo (16). Some in vivo
results supporting our present findings come from recent
rat studies where CsA (39, 40) or tacrolimus treatment (7)
caused glucose intolerance and inhibited adipocyte glu-
Figure 5. Cyclosporine A (CsA) and tacrolimus increase insulin-stimulated endocytosis of GLUT4myc in L6 cells, and have little effect on the
exocytosis. Confluent L6-GLUT4myc cells were incubated in the absence or presence of 100 nM insulin at 37°C for 30 minutes and thereafter
with antimyc antibody for 1 hour to label cell surface GLUT4myc. To measure the time course of internalization, cells were then rewarmed to allow
endocytosis in the absence (A) or presence of 100 nM insulin (B) and CsA or tacrolimus (100 nM) for 2–20 minutes. At the indicated times cells
were put on ice and the myc antibody-labeled GLUT4myc remaining on the surface was measured with the optical densitometry detection assay.
C: To measure the time course of stimulation, the cells were rewarmed to allow endocytosis in absence of insulin during 30 minutes. Cells were
then incubated in absence or presence of insulin (100 nM) and CsA or tacrolimus (100 nM) for 5, 10 or 20 minutes. Cells were placed on ice again
and the Myc antibody-labeled GLUT4myc remaining on the surface was analyzed by the OPD optical densitometry detection assay. The amount of
GLUT4myc remaining at the cell surface at any time point is expressed as a percentage of the cell surface GLUT4myc level at 0 minutes of
incubation. Data points are mean  SEM of 4–5 separate experiments each performed in duplicates. Line, single exponential fits. Rate constants
for endocytosis (ken) were calculated from single exponential fits. *P  .05 CsA or tacrolimus and insulin-treated vs. insulin.
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cose uptake, without affecting insulin-stimulated phos-
phorylation of key insulin signaling proteins.
In conclusion, we have demonstrated that the calcineu-
rin inhibitors CsA and tacrolimus, at therapeutic concen-
trations, impair glucose uptake in human subcutaneous
and omental adipocytes and in L6muscle cells. The effects
appear to be independent of the insulin signaling cascade.
Our data in L6 cells also suggest that CsA and tacrolimus
reduce amount of GLUT4 at the plasma membrane in the
presence of insulin and this process is mediated via en-
hanced rate of GLUT4 endocytosis. That may contribute
to impaired glucose handling in peripheral tissues, and
diabetes occurring in organ-transplanted patients. Con-
versely, these findings could potentially point to novel
pharmacological mechanisms to inhibit GLUT4 endocy-
tosis and increase its cell surface availability. Such a treat-
ment approach would enhance cellular glucose uptake
and improve glycaemic control in diabetes caused by cal-
cineurin inhibitor therapy. Potentially, it may also be ef-
fective in other forms of diabetes.
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